Dolutegravir Interactions with HIV-1 Integrase-DNA: Structural Rationale for Drug Resistance and Dissociation Kinetics

• Felix DeAnda,

  Affiliation Chemical Sciences, GlaxoSmithKline, Research Triangle Park, North Carolina, United States of America

  ⨯
• Kendra E. Hightower,

  Affiliation Biological Sciences, GlaxoSmithKline, Research Triangle Park, North Carolina, United States of America

  ⨯
• Robert T. Nolte,

  Affiliation Chemical Sciences, GlaxoSmithKline, Research Triangle Park, North Carolina, United States of America

  ⨯
• Kazunari Hattori,

  Affiliation Discovery Chemistry, Shionogi & Co., Ltd., Osaka, Japan

  ⨯
• Tomokazu Yoshinaga,

  Affiliation Infectious Diseases, Shionogi & Co., Ltd., Osaka, Japan

  ⨯
• Takashi Kawasuji,

  Affiliation Chemistry Infectious Diseases, Shionogi & Co., Ltd., Osaka, Japan

  ⨯
• Mark R. Underwood

  * E-mail: mark.r.underwood@gsk.com

  Affiliation Medicines Development Infectious Diseases, GlaxoSmithKline, Research Triangle Park, North Carolina, United States of America

  ⨯